Claudin-5 Biomarker Detection for Mild Cognitive Impairment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting mild cognitive impairment lack effective, non-invasive biomarkers, particularly for the presymptomatic stage, leading to inadequate early intervention and treatment for dementia, as existing techniques are invasive and inconvenient for widespread screening.
Innovation Solution
Utilization of Claudin-5 as a biomarker in body fluids, specifically measured using an anti-Claudin-5 monoclonal antibody, to distinguish mild cognitive impairment from other neurodegenerative and mental disorders, facilitating early detection and prevention.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If cerebrospinal fluid collection is used to detect amyloid and tau proteins, then detection precision is improved, but ease of operation deteriorates due to invasiveness and hospitalization requirements
Solution Approach 1:
The patent extracts the detection target from cerebrospinal fluid to peripheral blood. By measuring amyloid and tau proteins in peripheral blood instead of cerebrospinal fluid, the method maintains detection capability while eliminating the need for lumbar puncture and hospitalization, thus resolving the contradiction between detection precision and ease of operation
Solution Approach 2:
The patent uses peripheral blood as an intermediary medium to indirectly detect brain pathology. Instead of directly sampling cerebrospinal fluid from the brain, the method measures protein levels in peripheral blood, which serves as a surrogate marker for brain amyloid and tau accumulation, thereby avoiding invasive procedures while maintaining diagnostic value
2Ease of operation
If questionnaire-based cognitive testing is used, then ease of operation is improved, but measurement precision deteriorates due to subjectivity
Solution Approach 1:
The patent replaces the mechanical/questionnaire-based cognitive assessment system with a biochemical detection system. Instead of relying on subjective questionnaire responses, the method objectively measures amyloid and tau protein levels in peripheral blood, substituting mechanical testing with biochemical analysis to improve measurement precision while maintaining ease of operation
3Productivity
If early detection in presymptomatic stage is pursued, then productivity of prevention is improved, but device complexity increases due to lack of practical biomarkers
Solution Approach 1:
The patent applies the universality principle by using the same peripheral blood sampling and protein measurement approach for multiple purposes: screening presymptomatic individuals, diagnosing mild cognitive impairment, and monitoring disease progression. This single method serves multiple functions in dementia detection and management, enabling early detection without increasing system complexity
Solution Approach 2:
The patent changes the detection parameter from cognitive questionnaire scores to biochemical protein levels in peripheral blood. By measuring amyloid and tau protein concentrations in accessible peripheral blood rather than using complex cognitive assessments or invasive cerebrospinal fluid analysis, the method enables simple early detection in presymptomatic stages
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Claudin-5 in body fluids provides a specific and effective means to identify mild cognitive impairment, enabling early detection and potentially delaying or preventing dementia, improving treatment outcomes and public health strategies.
Implementation Method 1
measured using an anti-Claudin-5 monoclonal antibody
Data Source
AI summary
Provided is a means for detecting a subject with mild cognitive impairment or assisting in the detection thereof.A biomarker for testing for mild cognitive impairment, comprising Claudin-5.